Treatment of Withdrawal Symptoms With NADA Acupuncture in Chronic Pain Patients

Assessment of NADA Acupuncture for Treatment of Withdrawal Symptoms During Gradual Opioid Withdrawal in Chronic Pain Patients

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03397212

Enrollment

Registered

2018-01-11

Start date

2018-01-15

Completion date

2024-01-15

Last updated

2018-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pain, Opiate Withdrawal Syndrome

Keywords

NADA

Brief summary

This project aims at examining the following hypotheses: * Treatment with NADA and clonidine reduces intensity of withdrawal symptoms to a greater extent than treatment with clonidine. * Opioid withdrawal improves pain, physical and mental functioning and reduces opioid consumption 3 months and 1 year after withdrawal.

Interventions

OTHERNADA acupuncture

Ear acupuncture protocol described by National Acupuncture Detoxification Association

OTHERSham acupuncture

Ear acupuncture using inactive sham points

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Chronic pain patients treated with opioids over 3 months * The patient's doctor or nurse assesses that there is an indication to opioid withdrawal and / or the patient wishes to withdraw. * The patient is motivated for opioid withdrawal * The patient has experienced withdrawal symptoms * The patient must be able to understand, speak and write Danish * The patient must be able to transport himself to the pain center

Exclusion criteria

* Children under 18 years old * External ear infection * Treatment with benzodiazepines. * Active substance abuse and alcohol abuse. * Contraindications for treatment with clonidine: * Allergy * Bradyarrhythmias caused by diseased sinus cube or AV block of 2nd or 3rd grade. * lactose intolerance * Heart failure * High medullary damage * Cardiac conduction disturbances * Pregnancy and breastfeeding

Design outcomes

Primary

Measure	Time frame	Description
Change in intensity of withdrawal symptoms	3 months and 1 year	Change in intensity of withdrawal symptoms assessed with Danish withdrawal symptom questionnaire

Secondary

Measure	Time frame	Description
Change in quality of life assessed with SF36	3 months and 1 year	Change in quality of life assessed with SF36

Countries

Denmark

Contacts

Primary ContactRomanas Polianskis, MD

romanas.polianskis@regionh.dk+45 35455233

Backup ContactJette Højsted, MD

jette.hoejsted@regionh.dk+45 35457383

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026